Literature DB >> 12458208

Mutational analyses of the p35-caspase interaction. A bowstring kinetic model of caspase inhibition by p35.

Guozhou Xu1, Rebecca L Rich, Clemens Steegborn, Tongpil Min, Yihua Huang, David G Myszka, Hao Wu.   

Abstract

Apoptosis is a highly regulated multistep process for programmed cellular destruction. It is centered on the activation of a group of intracellular cysteine proteases known as caspases. The baculoviral p35 protein effectively blocks apoptosis through its broad spectrum caspase inhibition. It harbors a caspase recognition sequence within a highly protruding reactive site loop (RSL), which gets cleaved by a target caspase before the formation of a tight complex. The crystal structure of the post-cleavage complex between p35 and caspase-8 shows that p35 forms a thioester bond with the active site cysteine of the caspase. The covalent bond is prevented from hydrolysis by the N terminus of p35, which repositions into the active site of the caspase to eliminate solvent accessibility of the catalytic residues. Here, we report mutational analyses of the pre-cleavage and post-cleavage p35/caspase interactions using surface plasmon resonance biosensor measurements, pull-down assays and kinetic inhibition experiments. The experiments identify important structural elements for caspase inhibition by p35, including the strict requirement for a Cys at the N terminus of p35 and the rigidity of the RSL. A bowstring kinetic model for p35 function is derived in which the tension generated in the bowstring system during the pre-cleavage interaction is crucial for the fast post-cleavage conformational changes required for inhibition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458208     DOI: 10.1074/jbc.M211607200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Evolutionary families of peptidase inhibitors.

Authors:  Neil D Rawlings; Dominic P Tolle; Alan J Barrett
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

Review 2.  The protein structures that shape caspase activity, specificity, activation and inhibition.

Authors:  Pablo Fuentes-Prior; Guy S Salvesen
Journal:  Biochem J       Date:  2004-12-01       Impact factor: 3.857

Review 3.  Viral subversion of apoptotic enzymes: escape from death row.

Authors:  Sonja M Best
Journal:  Annu Rev Microbiol       Date:  2008       Impact factor: 15.500

4.  Reactive-site cleavage residues confer target specificity to baculovirus P49, a dimeric member of the P35 family of caspase inhibitors.

Authors:  Michael P Guy; Paul D Friesen
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

5.  Caspase inhibitors of the P35 family are more active when purified from yeast than bacteria.

Authors:  Ingo L Brand; Srgjan Civciristov; Nicole L Taylor; Gert H Talbo; Delara Pantaki-Eimany; Vita Levina; Rollie J Clem; Matthew A Perugini; Marc Kvansakul; Christine J Hawkins
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

6.  Functional and biochemical characterization of the baculovirus caspase inhibitor MaviP35.

Authors:  I L Brand; M M Green; S Civciristov; D Pantaki-Eimany; C George; T R Gort; N Huang; R J Clem; C J Hawkins
Journal:  Cell Death Dis       Date:  2011-12-15       Impact factor: 8.469

Review 7.  Mechanisms Applied by Protein Inhibitors to Inhibit Cysteine Proteases.

Authors:  Livija Tušar; Aleksandra Usenik; Boris Turk; Dušan Turk
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

8.  Involvement of the miR-137-3p/CAPN-2 Interaction in Ischemia-Reperfusion-Induced Neuronal Apoptosis through Modulation of p35 Cleavage and Subsequent Caspase-8 Overactivation.

Authors:  He Wang; Qian Yu; Zai-Li Zhang; Hong Ma; Xiao-Qian Li
Journal:  Oxid Med Cell Longev       Date:  2020-12-10       Impact factor: 6.543

9.  The E. coli effector protein NleF is a caspase inhibitor.

Authors:  Sonja Blasche; Mario Mörtl; Holger Steuber; Gabriella Siszler; Shahista Nisa; Frank Schwarz; Inna Lavrik; Thomas M A Gronewold; Klaus Maskos; Michael S Donnenberg; Dirk Ullmann; Peter Uetz; Manfred Kögl
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.